Department of Breast Cancer, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
PeerJ. 2024 Jul 10;12:e17667. doi: 10.7717/peerj.17667. eCollection 2024.
Advances in understanding the pathological mechanisms of breast cancer have resulted in the emergence of novel therapeutic strategies. However, triple-negative breast cancer (TNBC), a molecular subtype of breast cancer with a poor prognosis, lacks classical and general therapeutic targets, hindering the clinical application of several therapies to breast cancer. As insights into the unique immunity and molecular mechanisms of TNBC have become more extensive, immunotherapy has gradually become a valuable complementary approach to classical radiotherapy and chemotherapy. CD8+ cells are significant actors in the tumor immunity cycle; thus, research on TNBC immunotherapy is increasingly focused in this direction. Recently, CD8+ tissue-resident memory (TRM) cells, a subpopulation of CD8+ cells, have been explored in relation to breast cancer and found to seemingly play an undeniably important role in tumor surveillance and lymphocytic infiltration. In this review, we summarize the recent advances in the mechanisms and relative targets of CD8+ T cells, and discuss the features and potential applications of CD8+ TRM cells in non-luminal breast cancer immunotherapy.
对乳腺癌病理机制的深入理解催生了新的治疗策略。然而，三阴性乳腺癌（TNBC）作为乳腺癌的一种分子亚型，预后较差，缺乏经典和通用的治疗靶点，阻碍了几种针对乳腺癌的疗法的临床应用。随着对 TNBC 独特免疫和分子机制的认识不断深入，免疫疗法逐渐成为经典放化疗的一种有价值的补充方法。CD8+细胞是肿瘤免疫周期中的重要执行者；因此，TNBC 免疫疗法的研究越来越集中在这一方向。最近，CD8+组织驻留记忆（TRM）细胞作为 CD8+细胞的一个亚群，与乳腺癌的关系已被探索，并被发现似乎在肿瘤监测和淋巴细胞浸润中发挥着不可否认的重要作用。在这篇综述中，我们总结了 CD8+T 细胞的作用机制和相关靶点的最新进展，并讨论了 CD8+TRM 细胞在非腔性乳腺癌免疫治疗中的特征和潜在应用。
